---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-014315"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:20:28.261402+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Eton Pharmaceuticals launches HEMANGEOL Oral Solution for infantile hemangioma

## Summary
- HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy.
- Exclusively distributed through Anovo Specialty Pharmacy to streamline patient access and therapy initiation.
- Eton Cares support includes $0 co-pay for eligible commercially insured patients and expanded assistance programs.
- Estimated 5,000-10,000 infants treated annually in the U.S. with HEMANGEOL.
- Treatment window is typically 5 weeks to 5 months of age, lasting about 6 months.

## SEC filing metadata
- accession: 0001437749-26-014315
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926014315/0001437749-26-014315-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926014315/eton20260429_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-014315
- JSON: https://secwatch.observer/filing/0001437749-26-014315.json
- Plain text: https://secwatch.observer/filing/0001437749-26-014315.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.